AG473

AG473 is a small molecule pyrrolo[2,3-d]pyrimidine derivative designed as a microtubule-targeting antitumor agent. It functions by binding to the colchicine site of tubulin, which leads to microtubule depolymerization and the disruption of essential cellular processes such as division and transport. Developed by researchers at Duquesne University and the University of Texas Health Science Center at San Antonio, AG473 was optimized from a lead compound (AG346) to improve potency, achieving an EC50 of 8.4 nM for microtubule depolymerization. Preclinical studies indicate that AG473 is effective against human melanoma cell lines and can circumvent common drug resistance mechanisms, including the overexpression of P-glycoprotein (Pgp) and the βIII isotype of tubulin.